drugset
drugset / Trial / NCT06352632

ACT-GLOBAL Adaptive Platform Trial for Stroke

NCT06352632 ↗

Phase 3 Recruiting 20000 enrolled The George Institute Berry Consultants · collabUniversity of Calgary · collab
RandomizedFactorialSingle-blindTreatment

Summary

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

Timeline

Start
2024-09-26
Primary completion
2034-09
Completion
2034-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.225 mg/kg Other
Subject Alteplase Protein / enzyme biologic 0.45 mg/kg Other
Subject Colchicine Small molecule 0.5 mg Oral
Subject Deferoxamine Other / unclassified 32 mg/kg Intravenous
Subject NoNO-42 Unknown 2.6 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.0625 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.125 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.18 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous

Indications

stroke disorder